Oric Pharmaceuticals (NASDAQ:ORIC) Issues Earnings Results

Oric Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Oric Pharmaceuticals reported a quarterly loss of $0.44 per share, missing the consensus estimate of a $0.39 loss by $0.05.
  • Shares fell 4.3% on Monday to $7.52.
  • Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $21.25; 14 analysts rate the stock Buy, one Hold, and one Sell.
  • Interested in Oric Pharmaceuticals? Here are five stocks we like better.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.05), Zacks reports.

Oric Pharmaceuticals Stock Down 4.3%

Shares of ORIC stock traded down $0.34 on Monday, reaching $7.52. 1,196,157 shares of the stock were exchanged, compared to its average volume of 1,714,194. The stock has a market cap of $779.47 million, a P/E ratio of -5.57 and a beta of 1.23. The firm has a 50 day moving average of $11.56 and a two-hundred day moving average of $11.01. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.68.

Insider Transactions at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 14,000 shares of the company's stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total transaction of $189,420.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at $944,772.84. This represents a 16.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock worth $1,432,952 over the last ninety days. 5.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ORIC. Leerink Partners began coverage on shares of Oric Pharmaceuticals in a research report on Monday, October 5th. They issued an "outperform" rating and a $26.00 price objective for the company. BTIG Research restated a "buy" rating and set a $26.00 target price on shares of Oric Pharmaceuticals in a research report on Wednesday, October 28th. Wall Street Zen raised shares of Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, July 25th. JPMorgan Chase & Co. lifted their target price on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 14th. Finally, Stifel Nicolaus boosted their price target on Oric Pharmaceuticals from $14.00 to $18.00 and gave the company a "buy" rating in a report on Monday, October 26th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oric Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $21.25.

Read Our Latest Stock Report on ORIC

Oric Pharmaceuticals Company Profile

(Get Free Report)

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company's drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

See Also

Earnings History for Oric Pharmaceuticals (NASDAQ:ORIC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oric Pharmaceuticals Right Now?

Before you consider Oric Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.

While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines